GE HealthCare Technologies
GEHC
64.67
-0.10
-0.15%
GE HealthCare Technologies
US · GEHC
#689 by market cap
Listed 2022
64.67
-0.10
-0.15%
Live - 5344 symbols - heartbeat 219s ago
· 2026-10-08 08:27
Pre-market
64.67
0.00%
After-hours
64.67
0.00%
Overnight
64.55
-0.19%
- Market cap
- 29.21B
- P/E (TTM)i
- 14.90
- P/Bi
- 2.66
- EPSi
- 4.55
- Div yieldi
- 0.22%
- 52W posi
- 19%
Reader sentiment
Are you bullish or bearish on GEHC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.78, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year +4.84% YoY
Margins
- Gross margin
- 39.99%
- Operating margin
- 13.39%
- Net margin
- 10.10%
Key ratios & quality
- Enterprise valuei
- 34.86B
- PEG ratioi
- 5.24
- Altman Z-Scorei
- 1.78
PEG uses trailing P/E against the 3-year net income growth rate (2.84%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 16.63B | 17.16B | 17.59B | 18.34B | 19.55B | 19.67B | 20.63B |
| Gross profit | 6.55B | 6.77B | 7.17B | 7.18B | 7.92B | 8.21B | 8.25B |
| Selling & admin expenses | 3.59B | 3.24B | 3.56B | 3.63B | 4.28B | 4.27B | 4.23B |
| Research & development | 833.00M | 810.00M | 816.00M | 1.03B | 1.21B | 1.31B | 1.26B |
| Operating profit | 2.12B | 2.72B | 2.80B | 2.52B | 2.44B | 2.63B | 2.76B |
| Pretax profit | 2.09B | 2.71B | 2.88B | 2.51B | 2.36B | 2.58B | 2.77B |
| Tax | 410.00M | 652.00M | 600.00M | 563.00M | 743.00M | 531.00M | 614.00M |
| Net profit | 1.55B | 13.90B | 2.29B | 1.97B | 1.61B | 2.05B | 2.15B |
| Basic EPS | 3 | 30 | 5 | 4 | 3 | 4 | 5 |
| Diluted EPS | 3.35 | 30.45 | 4.94 | 4.22 | 3.03 | 4.34 | 4.55 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 4.78B | 5.01B | 5.14B | 5.70B | 5.13B | 5.30B |
| Gross profit | 2.01B | 1.98B | 1.99B | 2.26B | 1.98B | 2.18B |
| Selling & admin expenses | 1.04B | 1.03B | 1.05B | 1.11B | 1.12B | 1.12B |
| Research & development | 344.00M | 302.00M | 292.00M | 323.00M | 345.00M | 323.00M |
| Operating profit | 628.00M | 652.00M | 653.00M | 827.00M | 515.00M | 738.00M |
| Pretax profit | 692.00M | 613.00M | 643.00M | 821.00M | 505.00M | 693.00M |
| Tax | 104.00M | 113.00M | 179.00M | 219.00M | 94.00M | 119.00M |
| Net profit | 588.00M | 500.00M | 464.00M | 602.00M | 411.00M | 573.00M |
| Basic EPS | 1 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | 1.23 | 1.06 | 0.98 | 1.29 | 0.85 | 1.24 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | -- | 5.90B | 7.00B | 8.32B | 9.41B | 9.90B | 12.50B |
| Cash & ST investments | -- | 994.00M | 554.00M | 1.44B | 2.49B | 2.87B | 4.49B |
| Inventory | -- | 1.59B | 1.95B | 2.16B | 1.96B | 1.94B | 2.23B |
| Total assets | -- | 24.23B | 26.31B | 27.54B | 32.45B | 33.09B | 36.91B |
| Total current liabilities | -- | 6.52B | 6.76B | 7.19B | 8.98B | 9.55B | 9.11B |
| Short-term debt | -- | 132.00M | 110.00M | 119.00M | 1.12B | 1.62B | 642.00M |
| Long-term debt | -- | 31.00M | 31.00M | 8.23B | 8.44B | 7.45B | 9.50B |
| Total liabilities | -- | 9,477,000,000.00 | 9,412,000,000.00 | 17,947,000,000.00 | 25,144,000,000.00 | 24,437,000,000.00 | 26,307,000,000.00 |
| Total equity | -- | 14.75B | 16.90B | 9.59B | 7.31B | 8.65B | 10.60B |
| Retained earnings | -- | -- | -- | 0 | 1.33B | 3.26B | 5.28B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 9.74B | 11.31B | 11.89B | 12.50B | 10.43B | 10.50B |
| Cash & ST investments | 2.45B | 3.74B | 4.01B | 4.49B | 2.26B | 2.08B |
| Inventory | 2.16B | 2.28B | 2.30B | 2.23B | 2.35B | 2.48B |
| Total assets | 33.59B | 35.50B | 36.13B | 36.91B | 37.13B | 37.25B |
| Total current liabilities | 9.97B | 9.75B | 10.07B | 9.11B | 8.53B | 8.30B |
| Short-term debt | 2.12B | 2.13B | 2.14B | 642.00M | 139.00M | 133.00M |
| Long-term debt | 6.76B | 8.27B | 8.28B | 9.50B | 10.13B | 10.09B |
| Total liabilities | 24,168,000,000.00 | 25,547,000,000.00 | 25,907,000,000.00 | 26,307,000,000.00 | 26,227,000,000.00 | 26,028,000,000.00 |
| Total equity | 9.42B | 9.95B | 10.22B | 10.60B | 10.90B | 11.22B |
| Retained earnings | 3.81B | 4.30B | 4.71B | 5.28B | 5.65B | 6.20B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.99B | 1.69B | 1.61B | 2.11B | 2.10B | 1.95B | 1.99B |
| Depreciation & amortization | 659.00M | 630.00M | 625.00M | 633.00M | 610.00M | 580.00M | 578.00M |
| Free cash flow | 1.66B | 1.43B | 1.36B | 1.80B | 1.71B | 1.55B | 1.51B |
| Dividends paid | -- | -- | 0 | 0 | -41.00M | -55.00M | -64.00M |
| Stock buybacks / issuance | -- | -- | -- | -- | 0 | 0 | -200.00M |
| Ending cash balance | 869.00M | 1.01B | 561.00M | 1.45B | 2.51B | 2.89B | 4.52B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 250.00M | 94.00M | 593.00M | 1.05B | 290.00M | 168.00M |
| Depreciation & amortization | 136.00M | 148.00M | 148.00M | 146.00M | 153.00M | 160.00M |
| Free cash flow | 98.00M | 8.00M | 483.00M | 916.00M | 112.00M | 68.00M |
| Dividends paid | -16.00M | -16.00M | -16.00M | -16.00M | -16.00M | -16.00M |
| Stock buybacks / issuance | 0 | -100.00M | -100.00M | 0 | -100.00M | -200.00M |
| Ending cash balance | 2.48B | 3.77B | 4.03B | 4.52B | 2.29B | 2.11B |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | 94.02 | 14.32 | 14.73 | 16.80 | 25.59 | 22.14 |
| ROA %i | -- | 57.15 | 8.89 | 7.12 | 4.62 | 6.08 | 5.95 |
| ROIC %i | -- | 91.21 | 13.95 | 11.30 | 9.94 | 13.75 | 12.39 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | 33.09 | 18.72 |
| EBIT margin %i | 13.10 | 16.17 | 16.58 | 14.17 | 14.85 | 15.69 | 15.55 |
| FCF / sales %i | 9.97 | 8.32 | 7.73 | 9.83 | 8.77 | 7.88 | 7.30 |
| Current ratioi | -- | 0.90 | 1.04 | 1.16 | 1.05 | 1.04 | 1.37 |
| Quick ratioi | -- | 0.56 | 0.64 | 0.76 | 0.76 | 0.76 | 1.03 |
| Debt / assetsi | -- | 1.93 | 1.66 | 31.36 | 30.39 | 28.34 | 28.35 |
| LT debt / equityi | -- | 2.28 | 1.96 | 91.01 | 122.63 | 91.87 | 94.62 |
| Interest coveragei | 24.76 | 42.06 | 72.88 | 30.21 | 5.36 | 6.11 | 7.29 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 3.31 | 4.44 | 3.81 | 3.99 |
| Net income CAGR (3Y) %i | -- | -- | -- | 7.93 | -51.62 | -3.92 | 2.84 |
| FCF CAGR (3Y) %i | -- | -- | -- | 2.83 | 6.27 | 4.48 | -5.84 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 26.31 | 25.58 | 24.21 | 22.14 | 19.23 | 19.19 |
| ROA %i | 6.64 | 6.65 | 6.33 | 5.95 | 5.40 | 5.46 |
| ROIC %i | 14.51 | 13.83 | 12.99 | 12.39 | 11.28 | 10.88 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 16.36 | 16.30 | 15.94 | 15.55 | 14.33 | 14.52 |
| FCF / sales %i | 6.94 | 7.84 | 6.91 | 7.30 | 7.24 | 7.42 |
| Current ratioi | 0.98 | 1.16 | 1.18 | 1.37 | 1.22 | 1.26 |
| Quick ratioi | 0.68 | 0.84 | 0.86 | 1.03 | 0.82 | 0.84 |
| Debt / assetsi | 27.34 | 30.19 | 29.74 | 28.35 | 28.49 | 28.30 |
| LT debt / equityi | 76.88 | 88.39 | 86.11 | 94.62 | 97.84 | 94.83 |
| Interest coveragei | 6.78 | 7.08 | 7.24 | 7.29 | 7.06 | 7.25 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Advanced Imaging Solution (AIS) is the largest reported line at 71.22% of revenue, across 4 reported segments.
- The next-largest line, Pharmaceutical Diagnostics (PDx), is a distant second at 15.92% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Advanced Imaging Solution (AIS)71.22%
Pharmaceutical Diagnostics (PDx)15.92%
Patient Care Solutions (PCS)12.75%
Other0.11%
Quote time 2026-10-08 08:27:58 · For reference only, not investment advice and not tailored to your situation.